Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy Outcome

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yoshii, Yukie ^a   Furukawa, Takako ^a,b   Oyama, Nobuyuki ^b   Hasegawa, Yoko ^b   Kiyono, Yasushi ^b   Nishii, Ryuichi ^c   Waki, Atsuo ^a   Tsuji, Atsushi B ^a   Sogawa, Chizuru ^a   Wakizaka, Hidekatsu ^a   Fukumura, Toshimitsu ^a   Yoshii, Hiroshi ^a   Fujibayashi, Yasuhisa ^a,b   Lewis, Jason S ^d   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

^c UNIVERSITY OF MIYAZAKI HOSPITAL   (Japan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; FATTY ACID SYNTHASE; TETRAHYDROLIPSTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG UPTAKE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MICROARRAY ANALYSIS; MORPHOLOGY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ACETIC ACID; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENZYME INHIBITORS; FATTY ACID SYNTHASE, TYPE I; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LACTONES; MALE; MICE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING;

EID: 84878581951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064570     Document Type: Article

References (50)

1. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, et al. (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol Chem Hoppe-Seyler 367: 905-912.
2. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, et al. (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 101: 519-532.
3. Carvalho MA, Zecchin KG, Seguin F, Bastos DC, Agostini M, et al. (2008) Fatty acid synthase inhibition with orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int J Cancer 123: 2557-2565.
4. Puig T, Turrado C, Benhamu B, Aguilar H, Relat J, et al. (2009) Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 15: 7608-7615.
5. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW, (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64: 2070-2075.
6. Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, et al. (2003) Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 1: 707-715.
7. Yoshii Y, Waki A, Furukawa T, Kiyono Y, Mori T, et al. (2009) Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. Nucl Med Biol 36: 771-777.
8. Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, et al. (2001) Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 28: 117-122.
9. Yun M, Bang SH, Kim JW, Park JY, Kim KS, et al. (2009) The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma. J Nucl Med 50: 1222-1228.
10. Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS, (2008) 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49: 327-334.
11. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, et al. (2002) 11C-acetate PET imaging of prostate cancer. J Nucl Med 43: 181-186.
12. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, et al. (2003) 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44: 549-555.
13. Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, et al. (2009) 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 36: 422-427.
14. Czernin J, Benz MR, Allen-Auerbach MS, (2009) PET imaging of prostate cancer using 11C-acetate. PET Clin 4: 163-172.
15. Soloviev D, Tamburella C, (2006) Captive solvent [11C]acetate synthesis in GMP conditions. Appl Radiat Isot 64: 995-1000.
16. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS, (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958.
17. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 ΔΔCT method. Methods 25: 402-408.
18. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, et al. (2007) 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging-in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med 48: 420-428.
19. Dennis EA, (1997) The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci 22: 1-2.
20. Nagasaki S, Suzuki T, Miki Y, Akahira J, Kitada K, et al. (2009) 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 69: 1392-1399.
21. Canobbio I, Bertoni A, Lova P, Paganini S, Hirsch E, et al. (2001) Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem 276: 26022-26029.
22. Torti M, Bertoni A, Canobbio I, Sinigaglia F, Lapetina EG, et al. (1999) Rap1B and Rap2B translocation to the cytoskeleton by von Willebrand factor involves Fc gamma II receptor-mediated protein tyrosine phosphorylation. J Biol Chem 274: 13690-13697.
23. Xie Z, Gong MC, Su W, Turk J, Guo Z, (2007) Group VIA phospholipase A2 (iPLA2beta) participates in angiotensin II-induced transcriptional up-regulation of regulator of G-protein signaling-2 in vascular smooth muscle cells. J Biol Chem 282: 25278-25289.
24. Sato H, Taketomi Y, Isogai Y, Miki Y, Yamamoto K, et al. (2010) Group III secreted phospholipase A2 regulates epididymal sperm maturation and fertility in mice. J Clin Invest 120: 1400-1414.
25. Jelski W, Szmitkowski M, (2008) Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. Clin Chim Acta 395: 1-5.
26. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, et al. (2008) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26: 842-847.
27. Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, et al. (2002) Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci USA 99: 2830-2835.
28. Xu W, Li JY, (2010) SOX11 expression in mantle cell lymphoma. Leuk Lymphoma 51: 1962-1967.
29. Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY, (2011) Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a comparison with plasma vascular markers. Prostate 71: 1047-1053.
30. Oleksowicz L, Liu Y, Bracken RB, Gaitonde K, Burke B, et al. (2011) Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer. Prostate 72: 1140-1149.
31. Qian X, Li G, Vass WC, Papageorge A, Walker RC, et al. (2009) The tensin-3 protein, including its SH2 domain, is phosphorylated by Src and contributes to tumorigenesis and metastasis. Cancer Cell 16: 246-258.
32. Smalley MJ, Iravani M, Leao M, Grigoriadis A, Kendrick H, et al. (2007) Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res 9: R85.
33. Silina K, Zayakin P, Kalnina Z, Ivanova L, Meistere I, et al. (2011) Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother 34: 28-44.
34. Tauber S, Jais A, Jeitler M, Haider S, Husa J, et al. (2010) Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion. Mol Cancer 9: 200.
35. Guo N, Krutzsch HC, Inman JK, Roberts DD, (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57: 1735-1742.
36. Kim DM, Chung KS, Choi SJ, Jung YJ, Park SK, et al. (2009) RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells. Int J Cancer 125: 2520-2527.
37. Dai H, Huang Y, Li Y, Meng G, Wang Y, et al. (2012) TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma. Carcinogenesis 33: 30-40.
38. Watari A, Yutsudo M, (2003) Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 8: 5-9.
39. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
40. Menendez JA, Lupu R, (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7: 763-777.
41. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV, (2003) RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 63: 3799-3804.
42. Wang Y, Kelber JA, Tran Cao HS, Cantin GT, Lin R, et al. (2010) Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression. Proc Natl Acad Sci USA 107: 10920-10925.
43. Locke JA, Guns ES, Lehman ML, Ettinger S, Zoubeidi A, et al. (2010) Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate 70: 239-251.
44. Hyde CA, Missailidis S, (2009) Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 9: 701-715.
45. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, et al. (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12: 101-107.
46. Choi JI, Kim YB, Yang SO, Lee JK, Jung TY, (2011) Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean J Urol 52: 461-465.
47. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, et al. (2012) The clinical use of PET with 11C-acetate. Am J Nucl Med Mol Imaging 2: 33-47.
48. Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT, et al. (2006) Growth arrest induced by C75, A fatty acid synthase inhibitor, was partially modulated by p38 MAPK but not by p53 in human hepatocellular carcinoma. Cancer Biol Ther 5: 978-985.
49. Zhao W, Kridel S, Thorburn A, Kooshki M, Little J, et al. (2006) Fatty acid synthase: a novel target for antiglioma therapy. Br J Cancer 95: 869-878.
50. Salem N, Kuang Y, Corn D, Erokwu B, Kolthammer JA, et al. (2011) [(Methyl)1-11C]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol 13: 140-151.